Seidl C, Koch U, Buhleier T, Möller B, Wigand R, Markert E, Koller-Wagner G, Seifried E, Kaltwasser J P
Institut für Transfusionsmedizin und Immunhämatologie, Blutspendedienst Hessen, Frankfurt/Main, Germany.
J Rheumatol. 1999 Apr;26(4):773-6.
We have shown that HLA-DRB1 alleles influence inflammatory activity in patients with early active and severe rheumatoid arthritis (RA). Therefore, we analyzed the effect of HLA-DRB1 alleles on disease progression in patients with early RA during a clinical followup period of 18 months.
Disease progression was defined by the Larsen Score, the Ritchie Index (RI), and the Health Assessment Questionnaire (HAQ) score.
Patients carrying arthritogenic HLA-DRB1 alleles on one or both haplotypes are characterized by increased radiological joint destruction (Larsen Score). Further, (Q)R/KRAA homozygous patients were characterized by worse overall disease course (higher RI and HAQ). However, analysis of changes in joint effects (delta-RI) and personal disability (delta-HAQ) did not reveal significant differences between patients with or without disease associated HLA-DRB1 alleles.
The predisposing genetic pattern with disease associated HLA-DRB1 alleles did not profoundly influence the therapeutic outcome. Our data support the role of the HLA-DRB1 gene locus in disease modulation of RA. The genetic predisposition due to HLA-DRB1, however, may have only a limited influence on the therapeutic outcome in clinically severe cases of RA.
我们已经表明,HLA - DRB1等位基因会影响早期活动且严重的类风湿关节炎(RA)患者的炎症活动。因此,我们分析了HLA - DRB1等位基因在18个月临床随访期内对早期RA患者疾病进展的影响。
疾病进展通过 Larsen 评分、Ritchie 指数(RI)和健康评估问卷(HAQ)评分来定义。
在一个或两个单倍型上携带致关节炎HLA - DRB1等位基因的患者,其特征为放射学关节破坏增加(Larsen评分)。此外,(Q)R/KRAA纯合患者的特征为整体病程更差(RI和HAQ更高)。然而,对关节效应变化(Δ - RI)和个人残疾程度变化(Δ - HAQ)的分析未发现携带或不携带与疾病相关HLA - DRB1等位基因的患者之间存在显著差异。
携带与疾病相关HLA - DRB1等位基因的遗传易感性模式并未对治疗结果产生深远影响。我们的数据支持HLA - DRB1基因座在RA疾病调节中的作用。然而,HLA - DRB1导致的遗传易感性在临床严重的RA病例中可能仅对治疗结果产生有限的影响。